Sitaglendo Duo Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
MFDS item code 202200907 · Approved 2022.03.02
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help patients with type 2 diabetes control their blood sugar levels. It is beneficial for patients who have not previously received diabetes medication or have difficulty controlling blood sugar levels with monotherapy. Additionally, it may be utilized when monotherapy with metformin or sitagliptin is not sufficiently effective or when replacing combination therapy of both drugs. This medication can also be added as a complementary treatment when blood sugar control is inadequate during combination therapy with metformin and sulfonylureas or metformin and thiazolidinediones. When used in conjunction with insulin and if blood sugar control is challenging, this medication can be added to enhance the therapeutic effect. This multifaceted therapeutic approach improves blood sugar control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, “Patients who must not receive this medicine,” under Precautions for Use). 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, “General precautions,” under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, “Patients who must not receive this medicine,” under Precautions for Use).
This medication contains sitagliptin and metformin and is used for diabetes treatment. First, this medication may cause hypersensitivity reactions, so if allergic symptoms such as skin rash, difficulty breathing, or other reactions occur, discontinue use immediately and consult a physician. There is also a risk of serious inflammation of the pancreas called acute pancreatitis; thus, inform medical professionals immediately if symptoms like abdominal pain, vomiting, or nausea occur. This medication should not be administered to patients with severe renal impairment or those with acute heart failure, severe infections, or dehydration. Additionally, it should be temporarily discontinued before and after tests using iodinated contrast media. It is safest for pregnant women or those who are breastfeeding not to use this medication. This medication can cause lactic acidosis, which is rare but very serious, so if symptoms such as muscle pain, difficulty breathing, or weakness occur, visit the hospital immediately. While taking this medication, it is important to regularly monitor kidney function and blood tests to detect any abnormalities. This medication can induce hypoglycemia, so caution should be exercised during meals or increased physical activity, and the risk of hypoglycemia may be heightened when taken with other hypoglycemic agents. Alcohol consumption can increase the risk of lactic acidosis, so avoid drinking during treatment with this medication. In cases of surgery or severe illness, this medication should be temporarily discontinued, and resumed once the patient is stabilized. Patients taking this medication should consult a doctor immediately if blisters on the skin or severe joint pain occur. Finally, elderly patients may need dose adjustments and regular monitoring due to the possibility of decreased kidney function.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that is air-tight, at a temperature between 1 and 30 degrees Celsius. Proper storage maintains the effectiveness of the medication for a longer period.
Pink oval film-coated tablets
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.